<DOC>
	<DOCNO>NCT00922207</DOCNO>
	<brief_summary>This 3 arm study ass efficacy safety PEGASYS alone , combination Adefovir Entecavir patient HBeAg positive chronic hepatitis B . Patients randomize receive 1 ) PEGASYS 180 microgram sc weekly 48 week + placebo week -4 2 ; 2 ) PEGASYS 180 microgram sc weekly 48 week + Adefovir week -4 2 ; 3 ) PEGASYS 180 microgram sc weekly 48 week + Entecavir week -4 2 . Treatment follow 24 week treatment-free follow-up.The anticipated time study treatment 1 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Combination With Adefovir Entecavir Patients With HBeAg-Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>adult patient , 1865 year age ; HBeAg+ve &gt; =3 month ; positive serum HBV DNA within 3 month prior entry ; patient chronic hepatitis B , either naive HBV treatment , responded/relapsed nucleoside analogue ; &gt; =3 month treatmentfree interval nucleotide analogue . evidence decompensated liver disease ; history evidence medical condition associate chronic liver disease othr viral hepatitis ; coinfection active hepatitis A , C D , HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>